Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2021-04-23 Report Publication Anno…
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Calendrier financier 2021" (2021 Financial Calendar) and explicitly lists future dates for key corporate events such as 'Résultats annuels 2020' (Annual results 2020), 'Assemblée générale' (General Meeting), and 'Résultats semestriels 2021' (2021 Half-year results). This type of announcement, which communicates the schedule of future corporate events and reports, is best classified as a Report Publication Announcement (RPA), as it announces *when* other reports will be released, rather than being the report itself. The document length (4041 chars) is short, supporting the idea that it is an announcement rather than a full report (like a 10-K or IR).
2021-04-23 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly cites French regulatory articles (Code commerce and AMF General Regulation) and provides a table detailing the 'Nombre d'actions' (Number of shares) and 'Nombre total de droits de vote' (Total number of voting rights) as of a specific date (March 31, 2021, based on February 28, 2021 data). This type of regular disclosure concerning the total share capital and voting rights structure is a specific regulatory requirement, often related to major shareholding notifications or capital structure updates. Given the options, this most closely aligns with a notification regarding the capital structure or a specific regulatory filing. Since it details the total number of shares and voting rights, it is a direct disclosure of capital structure information, fitting best under 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ) if it were crossing a threshold, but the primary content is the capital count itself. However, none of the codes perfectly match a 'Total Voting Rights Disclosure'. Reviewing the definitions, 'SHA' (Share Issue/Capital Change) is the closest fit for a formal disclosure about the composition of the capital base, even if it's a routine monthly update rather than a specific issuance event. Alternatively, 'MRQ' (Major Shareholding Notification) is often used for changes in ownership, but this document reports the total count, which underpins those notifications. Given the explicit focus on the total number of shares and voting rights, 'SHA' is the most appropriate classification for a capital structure disclosure.
2021-03-31 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated March 25, 2021, issued by Advicenne to clarify a previous press release from March 19, 2021, regarding the anticipated European Marketing Authorization for ADV7103. This document is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing like a DVA or DIRS. It is an announcement providing an update on a regulatory/commercial event (imminent marketing authorization) and includes forward-looking statements and contact information. Since it is a specific announcement clarifying a prior communication, and it doesn't fit the definitions for ER (Earnings Release), DIV (Dividend), or CAP (Financing), it falls best under the general category for miscellaneous regulatory/corporate announcements, which is Regulatory Filings (RNS). It is not an announcement *about* a report being published (RPA), but rather a substantive update itself.
2021-03-25 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 25, 2021, providing a clarification ('Précision apportée') regarding a previous press release from March 19, 2021, concerning the expected marketing authorization for a drug candidate. This type of communication, which updates the market on specific operational or regulatory milestones outside of standard periodic financial reporting (like 10-K or IR), fits best under the general category of Regulatory Filings (RNS) or potentially an Earnings Release (ER) if it were tied to quarterly results, but here it is a specific operational update/correction. Since it is a formal announcement to the market regarding a specific event (clarification on regulatory timeline) and not a comprehensive report, a dividend notice, or a management change, it falls under the broad 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially an Earnings Release (ER) if the context implied it was part of a results package, but RNS is safer for specific, non-periodic updates. Given the content is a clarification on a regulatory expectation, RNS is the most appropriate fallback for a specific, non-standard announcement.
2021-03-25 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 19, 2021, announcing that Advicenne expects imminent European Marketing Authorization (MAA) for its drug candidate ADV7103 (Sibnayal™) for the treatment of dRTA. It also mentions the withdrawal of the Orphan Drug Designation application to expedite availability. This type of announcement, detailing significant operational and regulatory milestones (drug approval anticipation, strategic decisions regarding designations), is characteristic of an Earnings Release (ER) or a general regulatory/investor update. Since it focuses on key operational news and financial outlook implications rather than being a full financial report (like 10-K or IR) or a transcript (CT), the most fitting category is Earnings Release (ER), as these press releases often accompany or precede formal earnings announcements, or serve as major operational updates. It is not a 10-K (Annual Report), AR (Audit Report), IR (Interim Report), or CT (Call Transcript). It is a direct announcement of business progress, aligning best with ER, which covers key highlights and operational news.
2021-03-19 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated March 19, 2021, announcing that Advicenne anticipates imminent European Marketing Authorization for its product ADV7103 and has withdrawn its Orphan Drug Designation application to accelerate availability. It contains key business updates, CEO commentary, and forward-looking statements, typical of an initial announcement of significant corporate or product news. This format strongly aligns with an Earnings Release (ER) if it were tied to financial results, but since it is a specific operational/regulatory update that doesn't fit the defined categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it falls best under the general regulatory/news announcement category. Given the options, it is a significant corporate announcement that is not a full report (10-K, IR), a transcript (CT), or a specific financial filing like a proxy (PSI) or director dealing (DIRS). It is most similar to an Earnings Release (ER) in structure (press release format with highlights and commentary), but since the content is purely operational/regulatory progress rather than financial results, the most appropriate general category for significant, non-standard announcements is Regulatory Filings (RNS), as it is a formal communication to the market about regulatory progress, or potentially an Earnings Release (ER) if we interpret 'Earnings Release' broadly as 'Periodical Announcement'. However, since it is a specific, non-financial-period-ending announcement, and it is not a full report, RNS serves as the best fit for a general regulatory update that doesn't match other specific codes. Given the context of pharmaceutical progress announcements, RNS is the most suitable fallback for significant, non-financial-period-specific news.
2021-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.